Surrozen, Inc./DE Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss)
Surrozen, Inc./DE (SRZN) reported Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss) of $39.25 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:DerivativeFairValueHedgeIncludedInEffectivenessGainLoss · last filed 2026-08-06
- Surrozen, Inc./DE derivative, fair value hedge, included in effectiveness, gain (loss) for the quarter ending 2026-06-30 was $39.25M, a 24.52% increase year-over-year.
- Surrozen, Inc./DE derivative, fair value hedge, included in effectiveness, gain (loss) for the quarter ending 2026-03-31 was -$76.86M, a 570.35% decline year-over-year.
- Surrozen, Inc./DE derivative, fair value hedge, included in effectiveness, gain (loss) for the quarter ending 2025-12-31 was -$111.96M.
- Surrozen, Inc./DE derivative, fair value hedge, included in effectiveness, gain (loss) for the quarter ending 2025-09-30 was -$40.75M.
- Surrozen, Inc./DE derivative, fair value hedge, included in effectiveness, gain (loss) for fiscal 2025 was -$104.85M.
- Surrozen, Inc./DE derivative, fair value hedge, included in effectiveness, gain (loss) for fiscal 2024 was $0.00.
| Period end | Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss) 3 month | Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss) 6 month | Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss) 9 month | Derivative, Fair Value Hedge, Included in Effectiveness, Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.25M 10-Q · filed 2026-08-06 | -$37.61M 10-Q · filed 2026-08-06 | -$149.57M derived: sum of 3 quarters · filed 2026-08-06 | -$190.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$76.86M 10-Q · filed 2026-05-06 | -$188.81M derived: sum of 2 quarters · filed 2026-05-06 | -$229.56M derived: sum of 3 quarters · filed 2026-05-06 | -$198.04M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$111.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$152.71M derived: sum of 2 quarters · filed 2026-03-23 | -$121.19M derived: sum of 3 quarters · filed 2026-08-06 | -$104.85M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$40.75M 10-Q · filed 2025-11-07 | -$9.23M derived: sum of 2 quarters · filed 2026-08-06 | $7.11M 10-Q · filed 2025-11-07 | $7.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $31.52M 10-Q · filed 2026-08-06 | $47.86M 10-Q · filed 2026-08-06 | $47.86M derived: sum of 3 quarters · filed 2026-08-06 | $47.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $16.34M 10-Q · filed 2026-05-06 | $16.34M derived: sum of 2 quarters · filed 2026-05-06 | $16.34M derived: sum of 3 quarters · filed 2026-05-06 | $16.34M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $0.00 derived: sum of 2 quarters · filed 2026-03-23 | $0.00 derived: sum of 3 quarters · filed 2026-03-23 | $0.00 10-K · filed 2026-03-23 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-07 | $0.00 derived: sum of 2 quarters · filed 2025-11-07 | $0.00 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-08 | $0.00 10-Q · filed 2025-08-08 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |